TREATMENT OF TUBERCULOSIS PATIENTS WITH EXTENSIVE DRUG RESISTANCE USING NEW ANTI-TUBERCULOSIS DRUGS IN THE CIVILIAN COMMUNITY OF ARKHANGELSK REGION

• Published in: Tuberculosis and lung diseases
• Main Authors: Anastasiya I. Gayda, Oksana M. Sveshnikova, Viktoriya N. Verkhovaya, Svetlana V. Makhmaeva, Elena I. Nikishova, Andrey O. Maryandyshev
• Format: Article in Journal/Newspaper
• Language: Russian
• Published: New Terra Publishing House 2018
• Subjects: туберкулез с широкой лекарственной устойчивостью микобактерий; лечение; новые препараты; Diseases of the respiratory system; RC705-779; Arkhangelsk
• Online Access: https://doi.org/10.21292/2075-1230-2018-96-7-5-10; https://doaj.org/article/754f2776f784408cb16ecac4d54490d4

The objective: to assess treatment outcomes in tuberculosis patients with extensive drug resistance (XDR TB) treated by new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region.The analysis included all cases of XDR TB registered in the civilian community of Arkhangelsk Region from November 2006 to December 2013; treatment outcomes were assessed in 21 patients who were treated by regimens containing new anti-tuberculosis drugs (bedaquiline, delamanid, linezolid, clofazimine, imipenem with amoxiclav). 16 patients were treated by regimens containing 4 new anti-tuberculosis drugs. 2 patients were treated by regimen IV containing two drugs – bedaquiline, linezolid and bedaquiline, clofazimine; and 3 patients with regimens containing bedaquiline only.From November 2006 to December 2017, 175 XDR TB patients were registered in Arkhangelsk Region. The effective chemotherapy using new drugs made 57%, and mortality made 4.7%. In-take of new anti-tuberculosis drugs was accompanied side effects of minor and moderate degree.New anti-tuberculosis drugs are to be studied further in order to work out the most effective regimens for treatment of XDR TB patients.